Cargando…

Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines

Prognosis in patients suffering from high‐risk, refractory and relapsed germ cell tumours (GCT) often comprising of CD30‐positive embryonal carcinoma (EC) components remains poor. Thus, novel treatment strategies are warranted. The antibody‐drug conjugate (ADC) brentuximab vedotin delivers the poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönberger, Stefan, van Beekum, Cornelius, Götz, Barbara, Nettersheim, Daniel, Schorle, Hubert, Schneider, Dominik T., Casati, Anna, Craveiro, Rogerio B., Calaminus, Gabriele, Dilloo, Dagmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742680/ https://www.ncbi.nlm.nih.gov/pubmed/28941150 http://dx.doi.org/10.1111/jcmm.13344

Ejemplares similares

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
por: Bartlett, Nancy L, et al.
Publicado: (2014)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30(+) Lymphoma
por: Tudesq, Jean-Jacques, et al.
Publicado: (2017)

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
por: Li, Hong, et al.
Publicado: (2017)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
por: Lobastova, Liudmila, et al.
Publicado: (2021)

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Oral mycosis fungoides with CD30(+) large cell transformation successfully treated with brentuximab vedotin
por: Goggins, Clare A., et al.
Publicado: (2019)

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas
por: Wagner, Sandro M., et al.
Publicado: (2020)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin
por: Thakkar, Keval, et al.
Publicado: (2023)

Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
por: Zhao, Baiteng, et al.
Publicado: (2016)

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
por: Sharman, Jeffrey P., et al.
Publicado: (2019)

Brentuximab Vedotin
Publicado: (2012)

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
por: Svoboda, Jakub, et al.
Publicado: (2020)

Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
por: Savage, Kerry J., et al.
Publicado: (2022)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy
por: Baba, Yuta, et al.
Publicado: (2022)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
por: Kim, Youn H., et al.
Publicado: (2021)

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study
por: Rausch, Christian, et al.
Publicado: (2022)

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
por: Ogura, Michinori, et al.
Publicado: (2014)

Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature
por: Delacruz, Wilfred, et al.
Publicado: (2016)

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
por: Kim, Seok Jin, et al.
Publicado: (2020)

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
por: Horwitz, S., et al.
Publicado: (2022)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
por: Popova, Tanya Naskova, et al.
Publicado: (2018)

PB2351: TRIAL IN PROGRESS: A PHASE 2, MULTICENTRE STUDY OF BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT OF CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS
por: Song, Yuqin, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
por: Hong, Jennifer, et al.
Publicado: (2021)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8kmgrn8mokk1smbgpp4m0ji5j1